A Phase I/II trial of SX-682 in combination with bintrafusp alfa which targets PD-L1, transforming growth factor beta (TGF-β), and CV301, a poxviral vaccine designed against carcinoembryonic antigen (CEA) and mucin 1 (MUC1) tumor antigens in advanced refractory pancreaticobiliary cancer showed durable biochemical responses and disease control [67]. Here, MUC1 is linked to neoplasm.